<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
"http://www.w3.org/TR/REC-html40/loose.dtd"> 
<html>
<head>
<title>Untitled Document</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8">
</head>
<body>
<p>

# en/1.xml.gz<br>
# mt/1.xml.gz

<p><hr>
(src)="1"> The full EPAR for Improvac can be found on the Agency 's website : ema.europa.eu / Find medicine / Veterinary medicines / European public assessment reports . <br>
(trg)="1"> ema.europa.eu / Find medicine / Veterinary medicines / European public assessment reports . <br>
<hr>
(src)="2"> This summary was last updated in September 2017 . <br>
(trg)="2"> Dan is - sommarju ġie aġġornat l - aħħar f'Settembru 2017 . <br>
<hr>
(src)="3"> EPAR summary for the public <br>
(trg)="3"> Sommarju tal - EPAR għall - pubbliku <br>
<hr>
(src)="4"> The most common side effects with Improvac ( which may affect more than 1 in 10 pigs ) are injection site swelling , which gradually resolves but in 20 to 30 % of animals will last for more than 6 weeks , and a short-lived increase in body temperature of around 0.5 ˚ C within 24 hours of vaccination . <br>
(trg)="4"> L - effetti sekondarji l - aktar komuni b'Improvac ( li jistgħu jaffettwaw aktar minn 1 minn kull 10 ħnieżer ) huma nefħa fis - sit tal - injezzjoni , li titlaq gradwalment iżda f ' 20 sa 30 % tal - annimali ddum għal aktar minn 6 ġimgħat , u żieda fit - temperatura tal - ġisem li ma ddumx ta ' madwar 0.5 ˚ C fi żmien 24 siegħa mit - tilqim . <br>
<hr>
(src)="5"> The European Commission granted a marketing authorisation valid throughout the EU for Improvac on 11 May 2009 . <br>
(trg)="5"> Il - Kummissjoni Ewropea tat awtorizzazzjoni għat - tqegħid fis - suq valida fl - UE kollha għal Improvac fil - 11 ta ' Mejju 2009 . <br>
<hr>
(src)="6"> Other information about Improvac ? <br>
(trg)="6"> Informazzjoni oħra dwar Improvac ? <br>
<hr>
(src)="7"> This is a summary of the European public assessment report ( EPAR ) for Improvac . <br>
(trg)="7"> Dan huwa sommarju tar - rapport pubbliku Ewropew ta ' valutazzjoni ( EPAR ) għal Improvac . <br>
<hr>
(src)="8"> What are the risks associated with Improvac ? <br>
(trg)="8"> X'inhuma r - riskji assoċjati ma ' Improvac ? <br>
<hr>
(src)="9"> The first injection is from 8 weeks of age and the second 4 to 6 weeks before slaughter . <br>
(trg)="9"> L - ewwel injezzjoni hija mill - età ta ' 8 ġimgħat u t - tieni 4 sa 6 ġimgħat qabel il - qtil . <br>
<hr>
(src)="10"> The active substance in Improvac is an analogue of ( similar to ) gonatadotropin releasing factor ( GnRF ) linked to a carrier protein obtained from the bacterium Corynebacterium diphtheriae . <br>
(trg)="10"> Is - sustanza attiva f'Improvac hija analogu ta ' ( simili għal ) fattur li jirrilaxxa l - gonatadotropin ( GnRF ) marbut ma ' proteina ġarriera miksuba mill - batterju Corynebacterium diphtheriae . <br>
<hr>
(src)="11"> This temporarily inhibits release of steroids from the testicles , including androstenone , one of the two causes of boar taint . <br>
(trg)="11"> Dan jinibixxi b'mod temporanju r - rilaxx ta ' sterojdi mit - testikoli , inkluż androstenone , wieħed miż - żewġ kawżi ta ' riħa jew togħma tal - ħanżir . <br>
<hr>
(src)="12"> Androstenone and skatole levels are reduced from 4 to 6 weeks after the second injection and reduction of aggression and sexual behaviour is seen from 1 to 2 weeks after the second injection . <br>
(trg)="12"> Il - livelli ta ' androstenone u skatole jitnaqqsu minn 4 sa 6 ġimgħat wara t - tieni injezzjoni u t - tnaqqis fl - aggressjoni u fl - imġiba sesswali jidher minn ġimgħa sa ġimagħtejn wara t - tieni injezzjoni . <br>
<hr>
(src)="13"> Boar taint is caused by the production and build-up of the natural compounds androstenone and skatole in the flesh of these animals . <br>
(trg)="13"> Ir - riħa jew it - togħma tal - ħanżir tiġi kkawżata mill - produzzjoni u l - akkumulazzjoni tal - komposti naturali androstenone u skatole fil - laħam ta ' dawn l - annimali . <br>
<hr>
(src)="14"> Improvac works by stimulating the pig 's immune system to produce antibodies against gonadotropin-releasing hormone ( GnRH ) , part of the system that controls sexual development . <br>
(trg)="14"> Improvac jaħdem billi jistimula s - sistema immuni tal - ħanżir biex tipproduċi antikorpi kontra ormon li jirrilaxxa l - gonatadotropin ( GnRH ) , parti mis - sistema li tikkontrolla l - iżvilupp sesswali . <br>
<hr>
(src)="15"> Improvac contains the active substance gonadotropin releasing factor ( GnRF ) analogue-protein conjugate . <br>
(trg)="15"> Improvac fih is - sustanza attiva konjugat ta ' analogu ta ' proteina ta ' fattur li jirrilaxxa gonadotropin ( GnRF ) . <br>
<hr>
(src)="16"> Improvac gonadotropin releasing factor ( GnRF ) analogue-protein conjugate <br>
(trg)="16"> Improvac konjugat ta ' analogu ta ' proteina ta ' fattur li jirrilaxxa l - gonadotropin ( GnRF , gonadotropin releasing factor ) <br>
<hr>
(src)="17"> The first injection had a limited effect , but the second injection is followed by production of antibodies against GnRF . <br>
(trg)="17"> L - ewwel injezzjoni kellha effett limitat , iżda t - tieni injezzjoni tiġi segwita mill - produzzjoni ta ' antikorpi kontra <br>
<hr>
(src)="18"> Why is Improvac approved ? <br>
(trg)="18"> Għaliex ġie approvat Improvac ? <br>
<hr>
(src)="19"> For the full list of restrictions and all side effects reported with Improvac , see the package leaflet . <br>
(trg)="19"> Għal - lista sħiħa ta ' restrizzjonijiet u tal - effetti sekondarji kollha rrappurtati b'Improvac , ara l - fuljett ta ' tagħrif . <br>
<hr>
(src)="20"> Two studies showed reduction of aggression and mounting from 1 to 2 weeks after the second injection of Improvac , while the third studied the long term effect on aggression and mounting after 4 weeks only . <br>
(trg)="20"> Żewġ studji wrew tnaqqis ta ' aggressjoni u rkib minn ġimgħa sa ġimagħtejn wara t - tieni injezzjoni ta ' Improvac , filwaqt li t - tielet wieħed studja l - effett fit - tul fuq l - aggressjoni u l - irkib wara biss 4 ġimgħat . <br>
<hr>
(src)="21"> These may include a temporary reduction in sex hormone levels and reduced ability to reproduce in men and in women , including problems with pregnancy . <br>
(trg)="21"> Dawn jistgħu jinkludu tnaqqis temporanju fil - livelli tal - ormon sesswali u abbiltà mnaqqsa għar - riproduzzjoni fl - irġiel u fin - nisa , inkluż problemi fit - tqala . <br>
<hr>
(src)="22"> Improvac also reduces aggressive and sexual ( mounting ) behaviour in pigs . <br>
(trg)="22"> Improvac itejjeb ukoll l - imġiba aggressiva u sesswali ( irkib ) fil - ħnieżer . <br>
<hr>
(src)="23"> In a number of field studies pigs treated with Improvac were comparable to surgically castrated pigs in terms of levels of androstenone and skatole at slaughter . <br>
(trg)="23"> F'numru ta ' studji fuq il - post , il - ħnieżer ikkurati b'Improvac kienu komparabbli għal ħnieżer kastrati b'kirurġija f'termini ta ' livelli ta ' androstenone u skatole mal - qtil . <br>
<hr>
(src)="24"> Three field studies investigated the effectiveness of Improvac in reducing aggression and sexual behaviour in pigs . <br>
(trg)="24"> Tliet studji fuq il - post investigaw l - effettività ta ' Improvac fit - tnaqqis tal - aggressjoni u l - imġiba sesswali fil - ħnieżer . <br>
<hr>
(src)="25"> The Agency 's Committee for Medicinal Products for Veterinary Use ( CVMP ) concluded that Improvac 's benefits are greater than its risks and recommended that it be approved for use in the EU . <br>
(trg)="25"> Il - Kumitat għall - Prodotti Mediċinali għall - Użu Veterinarju ( CVMP ) tal - Aġenzija ddeċieda li l - benefiċċji ta ' Improvac huma akbar mir - riskji tiegħu u rrakkomanda li jkun approvat għall - użu fl - UE . <br>
<hr>
(src)="26"> Improvac also contains a compound derived from the sugar dextran as an adjuvant ( ingredient that strengthens the immune response ) . <br>
(trg)="26"> Improvac fih ukoll kompost derivat mid - dextran taz - zokkor bħala addittiv ( ingredjent li jsaħħaħ ir - rispons immuni ) . <br>
<hr>
(src)="27"> The full EPAR for Preotact can be found on the Agency 's website : ema.europa.eu / Find medicine / Human medicines / European Public Assessment Reports . <br>
(trg)="27"> ema.europa.eu / Find medicine / Human medicines / European Public Assessment Reports . <br>
<hr>
(src)="28"> This summary was last updated in 05-2012 . <br>
(trg)="28"> Dan is - sommarju ġie aġġornat l - aħħar fi : 05 - 2012 . <br>
<hr>
(src)="29"> Preotact significantly reduced the risk of having a vertebral fracture , in comparison with placebo : after 18 months , there were 42 vertebral fractures in the placebo group ( 3.37 ) and 17 in the Preotact group ( 1.32 ) . <br>
(trg)="29"> Preotact naqqas drastikament ir - riskju li jkun hemm ksur vertebrali , meta mqabbel ma ' plaċebo : wara 18 - il xahar , kien hemm 42 ksur vertebrali fil - grupp tal - plaċebo ( 3.37  ) u 17 fil - grupp ta ' Preotact ( 1.32  ) . <br>
<hr>
(src)="30"> Preotact was compared with placebo ( a dummy treatment ) . <br>
(trg)="30"> Preotact tqabbel ma ' plaċebo ( trattament finta ) . <br>
<hr>
(src)="31"> Preotact has been studied in one main study involving 2,532 women with postmenopausal osteoporosis . <br>
(trg)="31"> Preotact ġie studjat fi studju li involva 2,532 mara li jbatu minn osteoporożi ta ' wara l - menopawża . <br>
<hr>
(src)="32"> Preotact parathyroid hormone <br>
(trg)="32"> Preotact ormon paratirojdu <br>
<hr>
(src)="33"> This is a summary of the European public assessment report ( EPAR ) for Preotact . <br>
(trg)="33"> Dan id - dokument huwa sommarju tar - Rapport Pubbliku Ewropew ta ' Valutazzjoni ( EPAR ) għal Preotact . <br>
<hr>
(src)="34"> It is produced by a method known as ‘ recombinant DNA technology ' : the hormone is made by a bacterium that has received a gene ( DNA ) that makes it able to produce it . <br>
(trg)="34"> Dan huwa prodott b'metodu magħruf bħala ‘ teknoloġija rikombinanti tad - DNA ' : l - ormon huwa magħmul minn batterju li jkun irċieva ġene ( DNA ) li jagħmilha possibbli li jipproduċih . <br>
<hr>
(src)="35"> The most common side effects with Preotact ( seen in more than 1 patient in 10 ) are hypercalcaemia ( high blood calcium levels ) , hypercalciuria ( high calcium levels in the urine ) and nausea ( feeling sick ) . <br>
(trg)="35"> L - aktar effetti sekondarji komuni b'Preotact ( li dehru f'aktar minn pazjent 1 minn kull 10 ) huma liperkalsemija ( livelli għolja ta ' kalċju fid - demm ) , iperkalsjurja ( livelli għolja ta ' kalċju fl - awrina ) u nawżja ( tħossok ma tiflaħx ) . <br>
<hr>
(src)="36"> The European Commission granted a marketing authorisation valid throughout the European Union for Preotact on 24 April 2006 . <br>
(trg)="36"> Il - Kummissjoni Ewropea tat awtorizzazzjoni għat - tqegħid fis - suq għal Preotact valida fl - Unjoni Ewropea kollha fl - 24 ta ' April 2006 . <br>
<hr>
(src)="37"> The recommended dose of Preotact is 100 micrograms , given once a day as an injection under the skin into the abdomen . <br>
(trg)="37"> Id - doża rakkomandata ta ' Preotact hija ta ' 100 mikrogramma , darba kuljum bħala injezzjoni taħt ilġilda fl - addome . <br>
<hr>
(src)="38"> What is Preotact ? <br>
(trg)="38"> X'inhu Preotact ? <br>
<hr>
(src)="39"> Preotact is a medicine that contains the active substance parathyroid hormone . <br>
(trg)="39"> Preotact huwa mediċina li fih is - sustanza attiva ormon paratirojdu . <br>
<hr>
(src)="40"> • with unexplained high levels of alkaline phosphatase ( an enzyme ) , <br>
(trg)="40"> • persuni li jbatu minn disturbi li jaffettwa l - bilanċ tal - kalċju u l - fosfat fil - ġisem , <br>
<hr>
(src)="41"> Preotact contains parathyroid hormone , which stimulates bone formation by acting on osteoblasts ( bone forming cells ) . <br>
(trg)="41"> Preotact taħdem bħall - ormon biex tistimula l - formazzjoni tal - għadam billi taġixxi fuq osteoblasts ( ċelloli li jiffurmaw l - għadam ) . <br>
<hr>
(src)="42"> The parathyroid hormone in Preotact is identical to the human parathyroid hormone . <br>
(trg)="42"> L - ormon paratirojdu f'Preotact huwa l - istess bħall - ormon paratirojdu uman . <br>
<hr>
(src)="43"> Patients may also need to take calcium and vitamin D supplements if they do not have enough from their diet . <br>
(src)="44"> Preotact can be used for up to 24 months , after which patients can be treated with a bisphosphonate ( a medicine that reduces bone loss ) . <br>
(trg)="43"> Preotact jista ' jibqa ' jittieħed sa mhux aktar minn 24 xahar , imbagħad ilpazjenti jisgħu jkomplu jiġu kkurati bil - bisfosfonat ( mediċina li tnaqqas it - telf tal - għadam ) . <br>
<hr>
(src)="45"> Osteoporosis is more common in women after the menopause , when the levels of the female hormone oestrogen fall . <br>
(trg)="44"> Finnisa , l - osteoporożi hija aktar komuni wara l - menopawża , meta l - livelli tal - ormon tan - nisa , l - estroġenu , jaqgħu . <br>
<hr>
(src)="46"> When the cartridge is inserted in the special injection pen and the pen screwed together , or when the pre-filled pen is prepared for use , the powder and solvent mix to make up the solution for injection . <br>
(trg)="45"> It - tnaqqis tar - riskju kien inqas fin - nisa li diġà kellhom vertebra miksura fil - passat , u fin - nisa li diġà kellhom skor baxx tad - densità tal - għadam meta beda l - istudju , u dan jindika li kellhom spina aktar fraġli . <br>
<hr>
(src)="47"> Why has Preotact been approved ? <br>
(trg)="46"> Għaliex ġie approvat Preotact ? <br>
<hr>
(src)="48"> What is the risk associated with Preotact ? <br>
(trg)="47"> X'inhu r - riskju assoċjat ma ' Preotact ? <br>
<hr>
(src)="49"> Preotact is used for the treatment of osteoporosis ( a disease that makes bones fragile ) in postmenopausal women who are at high risk of fractures . <br>
(trg)="48"> Preotact wera li jnaqqas b'mod sinifikanti l - ksur vertebrali ( tas - sinsla tad - dahar ) , iżda mhux il - ksur fil - ġenbejn . <br>
<hr>
(src)="50"> • who have a bone disease that is not osteoporosis , <br>
(trg)="49"> • persuni li għandhom marda fl - għadam li mhix l - osteoporożi , <br>
<hr>
(src)="51"> The bone density was also the main measure in another study , which looked at the use of Preotact with or without alendronate ( a bisphosphonate ) . <br>
(trg)="50"> Id - densità tal - għadam kien ukoll il - kejl ewlieni fi studju ieħor , li ffoka fuq l - użu ta ' Preotact flimkien jew mingħajr l - alendronat ( bisfosfonat ) . <br>
<hr>
(src)="52"> How has Preotact been studied ? <br>
(trg)="51"> Kif ġie studjat Preotact ? <br>
<hr>
(src)="53"> EMA / 619580 / 2012 EMEA / H / C / 002568 <br>
(trg)="52"> EMEA / H / C / 002568 <br>
<hr>
(src)="54"> The full EPAR for Capecitabine Medac can be found on the Agency 's website : ema.europa.eu / Find medicine / Human medicines / European public assessment reports . <br>
(trg)="53"> ema.europa.eu / Find medicine / Human medicines / European public assessment reports . <br>
<hr>
(src)="55"> It is available as tablets ( 150 , 300 and 500 mg ) . <br>
(trg)="54"> Jiġi f'pilloli ( 150 , 300 u 500 mg ) . <br>
<hr>
(src)="56"> 5-FU is an analogue of pyrimidine . <br>
(trg)="55"> 5 - FU hu analogu tal - pirimidina . <br>
<hr>
(src)="57"> The European Commission granted a marketing authorisation valid throughout the European Union for Capecitabine Medac on 19 November 2012 . <br>
(trg)="56"> Il - Kummissjoni Ewropea tat awtorizzazzjoni għat - tqegħid fis - suq valida fl - Unjoni Ewropea kollha għal Capecitabine Medac fid - 19 ta ' Novembru 2012 . <br>
<hr>
(src)="58"> Capecitabine Medac capecitabine <br>
(trg)="57"> Aktar tagħrif dwar Capecitabine Medac <br>
<hr>
(src)="59"> It is used to treat : <br>
(trg)="58"> Jintuża għat - trattament ta ' : <br>
<hr>
(src)="60"> Capecitabine Medac is a ‘ generic ' and a ‘ hybrid ' medicine . <br>
(trg)="59"> Capecitabine Medac huwa mediċina ‘ ġenerika ' u ‘ ibrida ' . <br>
<hr>
(src)="61"> It is taken as tablets , while 5-FU normally needs to be injected . <br>
(trg)="60"> Tittieħed bħala pilloli , waqt li 5 - FU normalment tkun trid tiġi injettata . <br>
<hr>
(src)="62"> Pyrimidine is part of the genetic material of cells ( DNA and RNA ) . <br>
(trg)="61"> Il - pirimidina hi parti mill - materjal ġenetiku taċ - ċelloli ( DNA u RNA ) . <br>
<hr>
(src)="63"> This is a summary of the European public assessment report ( EPAR ) for Capecitabine Medac . <br>
(trg)="62"> Dan id - dokument huwa sommarju tar - Rapport Pubbliku Ewropew ta ' Valutazzjoni ( EPAR ) għal Capecitabine Medac . <br>
<hr>
(src)="64"> Treatment is continued for six months after colon surgery . <br>
(trg)="63"> It - trattament jitkompla għal sitt xhur wara l - intervent kirurġiku fil - kolon . <br>
<hr>
(src)="65"> • advanced gastric ( stomach ) cancer . <br>
(trg)="64"> • kanċer gastriku ( fl - istonku ) fi stadju avvanzat . <br>
<hr>
(src)="66"> Capecitabine Medac is taken twice a day at doses between 625 and 1,250 mg per square metre body surface area ( calculated using the patient 's height and weight ) . <br>
(trg)="65"> Capecitabine Medac jittieħed darbtejn kuljum b'dożi ta ' bejn 625 u 1,250 mg għal kull metru kwadru tas - superfiċje tal - ġisem ( li jiġi kkalkulat permezz tat - tul u l - piż tal - pazjent ) . <br>
<hr>
(src)="67"> While the reference medicine , Xeloda , is available as 150 and 500 mg tablets , Capecitabine Accord is also available as 300 mg tablets . <br>
(trg)="66"> Filwaqt li l - mediċina ta ' referenza , Xeloda , hija disponibbli f'pilloli ta ' 150 u 500 mg , Capecitabine Medac huwa disponibbli wkoll f'pilloli ta ' 300 mg . <br>
<hr>
(src)="68"> Capecitabine Medac is a medicine that contains the active substance capecitabine . <br>
(trg)="67"> Capecitabine Medac huwa prodott mediċinali li fih is - sustanza attiva kapesitabina . <br>
<hr>
(src)="69"> The CHMP concluded that , in accordance with EU requirements , Capecitabine Medac has been shown to have comparable quality and to be bioequivalent to Xeloda . <br>
(trg)="68"> Is - CHMP kkonkluda li , f'konformità mar - rekwiżiti tal - UE , Capecitabine Medac wera li għandu kwalità komparabbli u huwa bijoekwivalenti għal Xeloda . <br>
<hr>
(src)="70"> The company provided data from the published literature on capecitabine . <br>
(trg)="69"> Il - kumpanija pprovdiet dejta minn letteratura ppubblikata dwar il - kapesitabina . <br>
<hr>
(src)="71"> In the body , 5-FU takes the place of pyrimidine and interferes with the enzymes involved in making new DNA . <br>
(trg)="70"> Filġisem , 5 - FU jissostitwixxi l - pirimidina u jinterferixxi mal - enzimi li jieħdu sehem fil - produzzjoni ta ' DNA ġdid . <br>
<hr>
(src)="72"> Capecitabine Medac is an anticancer medicine . <br>
(trg)="71"> Capecitabine Medac huwa mediċina kontra l - kanċer . <br>
<hr>
(src)="73"> Capecitabine is a ‘ prodrug ' that is converted to 5-fluorouracil ( 5-FU ) in the body , but more is converted in tumour cells than in normal tissues . <br>
(trg)="72"> Il - kapesitabina hija ‘ promediċina ' li tiġi metabolizzata fil - ġisem bħala f ' 5 - fluorouracil ( 5 - FU ) , iżda fiċċelloli tat - tumuri din tiġi kkonvertita iktar f'ċelloli tal - kanċer milli f'tessuti b'saħħithom . <br>
<hr>
(src)="74"> Other information about Capecitabine Medac <br>
(trg)="73"> Capecitabine Medac kapesitabina <br>
<hr>
(src)="75"> The company carried out a ‘ bioequivalence ' study to show that 500 mg Capecitabine Medac produces the same levels of capecitabine in the blood as 500 mg Xeloda . <br>
(trg)="74"> Il - kumpanija wettqet studju ‘ bijoekwivalenti ' biex turi li 500 mg ta ' Capecitabine Medac jipproduċi listess livelli ta ' kapesitabina fid - demm bħat - teħid bħal 500 mg ta ' Xeloda . <br>
<hr>
(src)="76"> The active substance in Capecitabine Medac , capecitabine , is a cytotoxic medicine ( a medicine that kills cells that are dividing , such as cancer cells ) that belongs to the group ‘ anti-metabolites ' . <br>
(trg)="75"> Is - sustanza attiva f'Capecitabine Medac , il - kapesitabina , hija mediċina ċitotossika ( mediċina li toqtol iċċelloli li jkunu qed jimmultiplikaw , bħaċ - ċelloli tal - kanċer ) li jkunu parti mill - grupp tal - ‘ antimetaboliti ' . <br>
<hr>
(src)="77"> How has Capecitabine Medac been studied ? <br>
(trg)="76"> Kif ġie studjat Capecitabine Medac ? <br>
<hr>
(src)="78"> What are the benefits and risks of Capecitabine Medac ? <br>
(trg)="77"> X'inhu l - benefiċċju u r - riskju ta ' Capecitabine Medac ? <br>
<hr>
(src)="79"> Capecitabine Medac is used with other anticancer medicines , including a platinum-containing anticancer medicine such as cisplatin ; <br>
(trg)="78"> Capecitabine Medac jintuża flimkien ma ' medicini oħra kontra l - kanċer , inklużi mediċini kontra l - kanċer li jkun fihom il - platinu bħaċ - ċisplatina ; <br>
<hr>
(src)="80"> Capecitabine Medac tablets should be swallowed with water within 30 minutes after a meal . <br>
(trg)="79"> Il - pilloli ta ' Capecitabine Medac għandhom jittieħdu flimkien mal - ilma sa 30 minuta wara l - ikel . <br>
<hr>
(src)="81"> Why has Capecitabine Medac been approved ? <br>
(trg)="80"> Għaliex ġie approvat Capecitabine Medac ? <br>
<hr>
(src)="82"> • metastatic colorectal cancer ( cancer of the large bowel that has spread to other parts of the body ) . <br>
(trg)="81"> • kanċer kolorettali metastatiku ( kanċer tal - musrana l - għamja li jkun infirex għal partijiet oħra talġisem ) . <br>
<hr>
(src)="83"> Capecitabine Medac is used with or without other anticancer medicines in patients who have had surgery for ‘ stage III ' or ‘ Dukes ' stage C ' colon cancer ; <br>
(trg)="82"> • kanċer tal - kolon ( tal - musrana l - għamja ) . <br>
(trg)="83"> Capecitabine Medac jintuża waħdu jew ma ' mediċini oħra kontra l - kanċer f'pazjenti li kienu sottoposti għal intervent kirurġiku għal kanċer tal - kolon tal - ‘ fażi III ' jew ‘ fażi C ta ' Dukes ' ; <br>
<hr>
(src)="84"> For more information on generic and hybrid medicines , see the questionand-answer document here . <br>
(trg)="84"> Għal aktar tagħrif dwar il - mediċini ġeneriċi u ibridi , ara d - dokument mistoqsijiet - utweġibiet hawnhekk . <br>
<hr>
(src)="85"> What is Capecitabine Medac ? <br>
(trg)="85"> Għal xiex jintuża Capecitabine Medac ? <br>
<hr>
(src)="86"> Because Capecitabine Medac contains the same active substance as its reference medicine , its benefits and risks are taken as being the same as the reference medicine 's . <br>
(trg)="86"> Peress li Capecitabine Medac fih l - istess sustanza attiva bħall - mediċina ta ' referenza , il - benefiċċji u rriskji tiegħu jitqiesu l - istess bħal dawk tal - mediċina ta ' referenza . <br>
<hr>
(src)="87"> Capecitabine Medac is used with docetaxel ( another anticancer medicine ) after treatment with anthracyclines ( another type of anticancer medicine ) has failed . <br>
(trg)="87"> • kanċer tas - sider lokalment avvanzat jew metastatiku ( kanċer tas - sider li beda jinfirex ma ' partijiet oħra tal - ġisem ) . <br>
(trg)="88"> Capecitabine Medac jintuża ma ' docetaxel ( mediċina oħra kontra lkanċer ) wara li jkun falla trattament bl - antraċiklini ( tip ieħor ta ' mediċini kontra l - kanċer ) . <br>
<hr>
(src)="88"> This means that it is similar to a ‘ reference medicine ' , but it contains capecitabine at a new strength in addition to existing strengths . <br>
(trg)="89"> Dan ifisser li hija simili għal ‘ mediċina ta ' referenza ' iżda fiha l - kapesitabina f'qawwa ġdida minbarra l - qawwiet eżistenti . <br>
<hr>
(src)="89"> 6.2 Incompatibilities <br>
(trg)="90"> . 2 Inkompatibilitajiet <br>
<hr>
(src)="90"> gastric irritation <br>
(trg)="91"> irritazzjoni gastrika <br>
<hr>
(src)="91"> UNIQUE IDENTIFIER - 2D BARCODE <br>
(trg)="92"> IDENTIFIKATUR UNIKU - BARCODE 2D <br>
<hr>
(src)="92"> • Adults : <br>
(trg)="93"> • Adulti : <br>
<hr>
(src)="93"> INFORMATION ON BRAILLE <br>
(trg)="94"> INFORMAZZJONI BIL - BRAILLE <br>
<hr>
(src)="94"> Hard capsule . <br>
(trg)="95"> Kapsula iebsa . <br>
<hr>
(src)="95"> Gastrointestinal disorders common : <br>
(trg)="96"> Disturbi gastrointestinali komuni : <br>
<hr>
(src)="96"> Belgique / België / Belgien Recordati <br>
(trg)="97"> Belgique / België / Belgien <br>
<hr>
(src)="97"> 4.3 Contraindications <br>
(trg)="98"> 4.3 Kontra - indikazzjonijiet <br>
<hr>
(src)="98"> Recordati Rare Diseases Spain S.L.U. <br>
(trg)="99"> Recordati Rare Diseases Spain S . <br>
<hr>
(src)="99"> Reporting of side effects <br>
(trg)="100"> Rappurtar tal - effetti sekondarji <br>
<hr>
(src)="100"> System organ class <br>
(trg)="101"> Sistema tal - klassifika tal - organi <br>
<hr>
(src)="101"> The active substance is zinc . <br>
(trg)="102"> Is - sustanza attiva hi zinc . <br>
<hr>
</body>
</html>
